High resolution melting for mutation scanning of TP53 exons 5-8

被引:112
作者
Krypuy, Michael
Ahmed, Ahmed Ashour
Etemadmoghadam, Dariush
Hyland, Sarah J.
deFazio, Anna
Fox, Stephen B.
Brenton, James D.
Bowtell, David D.
Dobrovic, Alexander
机构
[1] Peter MacCallum Canc Ctr, Dept Pathol, Mol Pathol Res & Dev Lab, Melbourne, Vic 8006, Australia
[2] Li Ka Shing Ctr, Canc Res UK Cambridge Res Inst, Funct Genom Drug Resistance Lab, Cambridge CB2 0RE, England
[3] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia
[4] Peter MacCallum Canc Ctr, Ian Potter Ctr Genom & Predict Med, Melbourne, Vic 8006, Australia
[5] Univ Cambridge, MRC, Res Ctr, Cambridge CB2 2XZ, England
[6] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia
[7] Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia
关键词
D O I
10.1186/1471-2407-7-168
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: p53 is commonly inactivated by mutations in the DNA-binding domain in a wide range of cancers. As mutant p53 often influences response to therapy, effective and rapid methods to scan for mutations in TP53 are likely to be of clinical value. We therefore evaluated the use of high resolution melting (HRM) as a rapid mutation scanning tool for TP53 in tumour samples. Methods: We designed PCR amplicons for HRM mutation scanning of TP53 exons 5 to 8 and tested them with DNA from cell lines hemizygous or homozygous for known mutations. We assessed the sensitivity of each PCR amplicon using dilutions of cell line DNA in normal wild-type DNA. We then performed a blinded assessment on ovarian tumour DNA samples that had been previously sequenced for mutations in TP53 to assess the sensitivity and positive predictive value of the HRM technique. We also performed HRM analysis on breast tumour DNA samples with unknown TP53 mutation status. Results: One cell line mutation was not readily observed when exon 5 was amplified. As exon 5 contained multiple melting domains, we divided the exon into two amplicons for further screening. Sequence changes were also introduced into some of the primers to improve the melting characteristics of the amplicon. Aberrant HRM curves indicative of TP53 mutations were observed for each of the samples in the ovarian tumour DNA panel. Comparison of the HRM results with the sequencing results revealed that each mutation was detected by HRM in the correct exon. For the breast tumour panel, we detected seven aberrant melt profiles by HRM and subsequent sequencing confirmed the presence of these and no other mutations in the predicted exons. Conclusion: HRM is an effective technique for simple and rapid scanning of TP53 mutations that can markedly reduce the amount of sequencing required in mutational studies of TP53.
引用
收藏
页数:13
相关论文
共 35 条
  • [1] Alsner J, 2000, CLIN CANCER RES, V6, P3923
  • [2] Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan
    Amikura, T
    Sekine, M
    Hirai, Y
    Fujimoto, S
    Hatae, M
    Kobayashi, I
    Fujii, T
    Nagata, I
    Ushijima, K
    Obata, K
    Suzuki, M
    Yoshinaga, M
    Umesaki, N
    Satoh, S
    Enomoto, T
    Motoyama, S
    Nishino, K
    Haino, K
    Tanaka, K
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 100 (02) : 365 - 371
  • [3] CONSTANT DENATURANT GEL-ELECTROPHORESIS AS A RAPID SCREENING TECHNIQUE FOR P53 MUTATIONS
    BORRESEN, AL
    HOVIG, E
    SMITHSORENSEN, B
    MALKIN, D
    LYSTAD, S
    ANDERSEN, TI
    NESLAND, JM
    ISSELBACHER, KJ
    FRIEND, SH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) : 8405 - 8409
  • [4] TP53 and breast cancer
    Borresen-Dale, AL
    [J]. HUMAN MUTATION, 2003, 21 (03) : 292 - 300
  • [5] Disruption of p53 in human cancer cells alters the responses to therapeutic agents
    Bunz, F
    Hwang, PM
    Torrance, C
    Waldman, T
    Zhang, YG
    Dillehay, L
    Williams, J
    Lengauer, C
    Kinzler, KW
    Vogelstein, B
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) : 263 - 269
  • [6] DEPPERT W, 1990, ONCOGENE, V5, P1701
  • [7] P53 FUNCTIONS AS A CELL-CYCLE CONTROL PROTEIN IN OSTEOSARCOMAS
    DILLER, L
    KASSEL, J
    NELSON, CE
    GRYKA, MA
    LITWAK, G
    GEBHARDT, M
    BRESSAC, B
    OZTURK, M
    BAKER, SJ
    VOGELSTEIN, B
    FRIEND, SH
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (11) : 5772 - 5781
  • [8] ALTERATION OF THE P53 TUMOR-SUPPRESSOR GENE OCCURS INDEPENDENTLY OF K-RAS ACTIVATION AND MORE FREQUENTLY IN SEROUS ADENOCARCINOMAS THAN IN OTHER COMMON EPITHELIAL TUMORS OF THE HUMAN OVARY
    FUJITA, M
    ENOMOTO, T
    INOUE, M
    TANIZAWA, O
    OZAKI, M
    RICE, JM
    NOMURA, T
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1994, 85 (12): : 1247 - 1256
  • [9] Goi K, 1997, CANCER RES, V57, P1895
  • [10] Greenblatt MS, 2001, CANCER RES, V61, P4092